Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials
Executive Summary
FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman
You may also be interested in...
Genentech Plans Avastin Renal Cell Cancer, Breast Cancer sBLA Filings
Fueled by positive early data, Genentech is in discussions with FDA regarding a potential sBLA submission for Avastin (bevacizumab) for renal cell cancer, the company announced
Genentech Plans Avastin Renal Cell Cancer, Breast Cancer sBLA Filings
Fueled by positive early data, Genentech is in discussions with FDA regarding a potential sBLA submission for Avastin (bevacizumab) for renal cell cancer, the company announced
Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says
Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call